MedTech FluidAI Medical secures funding to empower healthcare providers with data-driven insights to transform postoperative care.

KITCHENER, ON, Oct. 10, 2023 – FluidAI Medical (FluidAI), a pioneer in leveraging artificial intelligence (AI) for postoperative patient monitoring, today announced that it has raised $15 million in Series A funding, led by SOSV and Graphene Ventures with participation from Boutique Venture Partners, Threshold Impact, Cur8 Capital, Leva Capital, Kyto Technology & Life Science Inc., Juno Pharmaceuticals, and a number of esteemed angels, funds and government funding organizations.

Following any surgical intervention, there are inherent risks of adverse outcomes, irrespective of how minor or major the procedure may be. These complications can range from infections, bleeding, and wound healing issues to significant disability or death. They not only jeopardize the health and recovery of the patient but also place additional burdens on the healthcare system, including prolonged hospital stays and increased medical expenses. Recognizing these complications early on is paramount for the comprehensive care of surgical patients.

Some of the most devastating complications that can arise after surgery are anastomotic leaks, which occur after surgery when there’s a connection (anastomosis) between two parts of the digestive tract. A leak from this connection can lead to serious complications, including sepsis (blood infection) and death. On average, the leak rate stands at 8% across various types of surgeries, but this can spike to as high as 30% in more complex procedures. The condition also comes with a concerning average mortality rate of 12%. Per 1,000 patients undergoing colorectal surgery in the United States, anastomotic leaks add an extra 9,500 days of hospital care and impose an average additional cost of about $50,000 per affected patient.

FluidAI’s first solution, Stream™ Platform, uses advanced sensors and an AI-driven algorithm that may prompt surgeons to identify these leaks earlier, helping surgeons achieve better clinical outcomes and efficiencies within the greater healthcare system. FluidAI’s timely funding underscores the industry’s pressing need for innovative solutions that can ensure patient safety, reduce hospital stays, and ultimately cut down healthcare costs.

“This funding not only validates our vision but also fuels our mission. At FluidAI, our goal is to continuously push the boundaries of what’s possible in postoperative care, ensuring patients recover safely and quickly. With the trust and support of our investors, we’re poised to make a monumental impact on how data informs care decisions,” said Youssef Helwa, CEO at FluidAI.

“FluidAI is a perfect example of AI-powered proprietary sensing being developed to save lives,” said Duncan Turner, SOSV GP. “With FluidAI, surgeons can ensure better clinical outcomes, shorter hospital stays for patients, and cost efficiencies across the healthcare ecosystem. We’re thrilled to back the FluidAI team, a passionate group of scientists, engineers and healthcare professionals who are leading this compelling development in post-operative care.”

“FluidAI is pushing the frontiers of AI for early postoperative leak monitoring in a way that could save many lives by detecting leaks earlier than what surgeons are accustomed to seeing today. Our investment marks a pivotal step in revolutionizing medical technology. Together, we are committed to a healthier, brighter future for all,” said Nabil Borhanu, Founder & Managing Partner, Graphene Ventures

The investment will allow FluidAI to expand into existing and new global markets, grow its dynamic team, amplify R&D efforts, and introduce novel AI-driven solutions catering to a broader range of postoperative complications.

About FluidAI Medical

FluidAI (formerly known as NERv Technology Inc.) is a Canadian medical technology company that uses AI to aid with the early detection of postoperative leaks. From general to gastrointestinal surgeries, FluidAI’s mission is to empower healthcare providers with data-driven solutions that improve patient outcomes and advance postoperative care. To learn more about FluidAI and how the company is transforming postoperative care, please visit https://fluidai.md/.

About SOSV

SOSV is a global, multi-stage venture capital firm dedicated to funding deep tech startups focused on human and planetary health. Operating programs like HAX, IndieBio, and Orbit Startups in cities from New York to Tokyo, the firm has backed nearly 1000 startups in 60 countries. As of April 2023, SOSV’s top health startups boast a combined valuation of $6.47 billion. The firm manages a $277 million core Fund IV and a $100 million Select Fund for follow-on investments, along with the Genesis Consortium that provides extra funding for select life sciences startups. With a diverse team and a portfolio representing 84 nationalities, SOSV is committed to accelerating global innovation. Learn more at https://sosv.com/.

About Graphene Ventures

Graphene Ventures is a venture capital firm established in 2015, specializing in direct investments in private technology companies. With offices in Palo Alto, Toronto, São Paulo, and Riyadh, the firm has a global reach and is dedicated to helping its portfolio companies scale into multiple markets. The lean but experienced team at Graphene brings decades of expertise in growing high-impact startups, uniquely positioning them to identify promising teams and innovative companies. Learn more at https://graphenevc.com/.

SOURCE Fluid AI Medical

Dwellr is an online marketplace that directly connects families with the best senior communities tailored to the needs of their loved ones.

LINCOLN, Neb., Oct. 10, 2023 — Dwellr, a Nebraska-based startup, has secured $500,000 in funding, led by Move Venture Capital and Invest Nebraska. This initial round of funding allows founders Davey Owens and Drew Tuzson to publicly launch the online marketplace that is designed to transform the way families find senior care by offering a direct connection between seniors and their desired communities.

Dwellr was founded because the founders discovered that searching for senior living is an extremely antiquated experience in 2023. Most senior living communities are forced into using traditional referral services, meaning families are required to fill out convoluted online forms and receive cold calls and emails from communities across the state.

“Getting dozens of calls a day from senior communities within a 50-mile radius to schedule a tour is extremely stressful during an already sensitive time,” stated Owens, CEO of Dwellr. “So we created an experience similar to how Zillow works, but for senior living.”

Dwellr’s mission goes beyond simplifying searches. It challenges the status quo of referral services that often prioritize commissions over genuine senior needs. With its user-friendly interface and direct communication channels, Dwellr ensures families can make informed decisions with higher confidence.

“Dwellr provides a user-friendly and streamlined experience for consumers searching for senior living options in their local area,” stated Thomas Cloutier, CMO of Arete Living, a Dwellr customer. “Just as leading household rental companies have succeeded, I believe Dwellr has the potential to establish itself as a household name in the senior living industry.”

With its initial launch targeting cities in Nebraska, Iowa, Missouri, and Colorado, Dwellr is gearing up to expand its services, aiming to set a new industry standard in senior care searches.

About Dwellr
Dwellr is an online marketplace revolutionizing the search for senior care facilities by offering a direct, transparent, and efficient platform that connects families with the best senior communities tailored to the needs of their loved ones.

Media Contact:
Davey Owens
Phone: (206) 293-7637
Email: davey@heydwellr.com

SOURCE Dwellr

STENNIS SPACE CENTER, Miss., Oct. 10, 2023 — Evolution Space, a Mojave, Calif.-based solid propulsion and launch provider, announced today with NASA Stennis that it has signed an agreement and begun construction on the first-ever solid propulsion center and solid rocket motor testing at the historic NASA Stennis Space Center. The company also announced the close of its bridge funding round on the heels of multiple successful flight missions in April and May of this year, enabling the execution of the deal with Stennis.

Located near the iconic NASA test stands, the Evolution Space Propulsion Center will repurpose former Mississippi Army Ammunition Plant facilities acquired by NASA in 2011. The center is scheduled for active operations in Q2, 2024, and will host the company’s 200-gallon propellant mixer, provide propellant storage, and serve as an operational base for static fire testing using the E-3 Test Complex.

“By partnering with NASA, we are able to rapidly stand up a facility which will add considerable capability to the U.S. solid rocket motor industrial base” said Manny Ballestero, U.S. Army Veteran and Evolution’s VP of Production and Development. “We look forward to the future of our partnership as we continue to expand our presence at Stennis.”

The ability for efficient interfacing with Evolution’s growing testing and flight operations in the Gulf region, in partnership with The Spaceport Company, factored heavily into the company’s site selection process. The deal also doubles down on NASA’s growing support of the private spaceflight sector.

“This is another great addition to South Mississippi’s commercial space engagement,” said Dr. Rick Gilbrech, Director of NASA Stennis Space Center. “Evolution Space gains access to critical NASA Stennis infrastructure and expertise as it continues to build its propulsion capabilities. In turn, we continue frontline work with commercial companies as we support NASA’s commitment to increase access to space and grow our federal city. We look forward to working with Evolution Space.”

The selection of South Mississippi was a personal one for Steve Heller, Evolution’s Founder, CTO and Chief Executive Officer, who traces the very beginnings of the company back to his earliest propulsion work as a child in nearby Clarke County, Mississippi. “We’re stoked to be part of NASA’s mission to create jobs and fuel South Mississippi’s local economy, and selfishly the full-circle angle is a cool one for me,” Heller said. “Mississippi is where my rocket journey started, and now we’re back to kick things into high gear.”

ABOUT NASA STENNIS SPACE CENTER
NASA Stennis in south Mississippi, the nation’s largest rocket propulsion test site and a growing aerospace and technology hub, has helped power American spaceflight since the mid-1960s.

ABOUT EVOLUTION SPACE
Evolution Space, based in Mojave, Calif., is a provider of rapidly-responsive solutions for the next generation of private spaceflight and defense. For more information visit www.evolutionspace.com. 

SOURCE Evolution Space

HUDDINGE, Sweden, Oct. 10, 2023 — XNK Therapeutics AB (“XNK”) today announced that it has applied for and been granted funding by Sweden’s innovation agency Vinnova. The grant consists of SME support through the Competence Center for Next-generation NK Cell-based Cancer Immunotherapy (NextGenNK). The competence center is coordinated by the Karolinska Institutet and XNK has been a member since the center’s inception in 2020. The funding amounts to up to 1.7 million SEK over two years and will be used in a specific preclinical program in XNK’s project portfolio.

For more information, please contact:
Johan Liwing, CEO, XNK Therapeutics
Tel: +46 706 70 36 75
E-mail: [email protected]

About XNK Therapeutics AB

XNK Therapeutics is a clinical stage immunotherapy company focused on bringing new and more effective treatments to cancer patients. The company is at the forefront of autologous NK cell-based cell therapy development with a proprietary technology platform and a pipeline spanning both hematological malignancies and solid tumor indications. The most advanced product, evencaleucel, is in phase II studies in combination with the CD38 antibody isatuximab targeting multiple myeloma. Other programs include XNK02 in AML, currently in advanced preclinical studies in collaboration with MD Anderson Cancer Center, XNK03 in bladder cancer, currently in preclinical studies in collaboration with the Karolinska University Hospital and XNK04 in preclinical studies in collaboration with a global pharma. XNK’s efforts are supported by a dedicated team that include world-renowned NK cell experts and by an approved in-house GMP facility. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit www.xnktherapeutics.com.

About NextGenNK

NextGenNK is a Competence Center for the development of next generation NK cell-based cancer immunotherapies. The Center is coordinated by Karolinska Institutet and collaborates with the Karolinska University Hospital and prominent national and international industrial partners. The Center was launched in 2020, and is jointly funded by Karolinska Institutet, the Industrial partners, and Vinnova, Sweden’s innovation agency.

The following files are available for download:

SOURCE XNK Therapeutics AB

AUSTIN, Texas, Oct. 10, 2023 — Saronic, a maritime autonomy company focused on surface vessels, announced today a $55 million Series A funding round led by Caffeinated Capital, with participation from 8VC, U.S. Innovative Technology Fund, Andreessen Horowitz, Lightspeed Venture Partners, Point72 Ventures, Silent Ventures, Overmatch Ventures, Ensemble VC, and Cubit Capital. This significant investment underscores Saronic’s commitment to addressing critical capability gaps at sea through attritable, autonomous platforms. With this raise, Saronic will accelerate research and development while expanding in-house manufacturing capacity for rapid production.

The need for these autonomous surface vessels is clear. To outpace China, America must start building a large fleet of autonomous vessels today. Saronic provides a state-of-the-art, purpose-built solution for the United States and its allies, seamlessly integrating software and hardware to optimize autonomous missions, enhancing the range, capability, and survivability of the naval fleet and the warfighter.

Saronic is the only company that can deliver this critical technology, filling a gap where shipbuilders, traditionally focused on manufacturing large naval ships, lack the capacity and expertise, while other vendors provide legacy platforms and struggle with production at scale.

“America’s conventional shipbuilding ecosystem lacks the agility to match the threats posed by our adversaries, and many proposed solutions for the fleet aren’t cohesively designed for the mission. Saronic stands apart,” said Dino Mavrookas, the company’s co-founder and CEO. “Saronic has worked closely with the Navy to build a solution that meets their requirements. We’re putting software, autonomy, and mission profiles first, reshaping design for rapid production and deployment, and creating a novel breed of autonomous vessels that can meet current and future threats.”

“Saronic is one of the most timely and ambitious companies we have ever partnered with – its technology will fundamentally transform how the Navy operates over the next century,” said Raymond Tonsing, founder and managing partner of Caffeinated Capital, which led the funding round. “We have been astounded by the speed at which this exceptional team has already begun to bridge the technology gap in naval autonomy.”

The company is currently developing Spyglass, a 6-foot vessel, and Cutlass, a 13-foot vessel, each outfitted with remotely updatable software and capable of carrying diverse payloads in communication-denied and GPS-denied environments. These systems enable real-time, collaborative, and autonomous mission-level decision-making, and are designed to navigate the challenges of maritime environments. Engineered as attritable systems, these vessels offer minimal life-cycle costs and considerable potential for scalability.

“Saronic has brought together the top talent from the innovation world, the military, and the defense industry to address the most critical strategic needs for our Navy,” said Joe Lonsdale, the managing partner of 8VC and co-founder of Saronic via the 8VC Build program.

“We are honored to have the backing of seasoned investors who are fully aligned with our mission to deliver top-tier technology to our warfighters as fast as possible,” said Rob Lehman, Saronic’s co-founder and Chief Commercial Officer. “This funding round will enable us to sustain our rapid growth, development, and delivery efforts.”

Saronic is a defense company with a dynamic blend of innovators, seasoned warfighters, and top-tier engineers and technologists from various fields, all dedicated to bringing autonomy to American and allied navies. This investment reflects a strong belief in the team’s capability to rapidly provide autonomous solutions tailored to the modern naval landscape.

Media contact: [email protected]

SOURCE Saronic

AUSTIN, Texas, Oct. 9, 2023 — MDisrupt, the leading expert marketplace for the healthtech industry, is excited to announce the successful completion of a $3 million seed funding round to accelerate their pivotal role in reshaping the healthtech innovation landscape. Backed by a powerhouse consortium of investors, this funding round was led by The Venture Collective, with participation from Capita3, 3plus VC, Geek Ventures, Mindshift Capital, The BFM Fund, Zane Venture Fund, Emmeline Ventures, Growth Factory and several other strategic investors in the healthcare and technology sectors. The funding injection will fuel MDisrupt’s plans to expand its client roster and turbocharge the launch of its Expert Marketplace platform, promising on-demand access to a league of top-tier clinicians and seasoned health experts.

MDisrupt’s vision is simple: to provide on-demand access to the most elite clinicians and seasoned health experts in the industry,to enable healthtech companies to build, commercialize and scale their health products responsibly. In an ever-evolving healthcare landscape, having healthcare domain experts at your fingertips is the key to building solutions that can enable widespread adoption and scale.

Ruby Gadelrab, Founder and CEO of MDisrupt, declared, “Healthcare is a complex ecosystem that requires an intricate and unique combination of clinical, commercial and regulatory expertise. We believe that in healthcare, the most important intelligence in healthcare is Human intelligence. For healthtech and life science companies, accessing domain experts at every step of the development and commercialization journey is the key to success in this arena. We are honored to have partnered with this exceptional group of investors who share our commitment to empowering the most impactful companies to bring their health solutions to patients quickly and responsibly.”

Founded in 2020, MDisrupt has built the ultimate healthcare marketplace, a platform that expertly matches professionals with healthtech and life science companies that are seeking specific fractional healthcare expertise on demand. A recent publication in the New England Journal of Medicine authored by Google’s health care leaders underscored the importance of embracing clinical experts – those that have a deep understanding of the healthcare system, and can realize the promise that technology offers to improve health at scale.

With the sector expected to witness a nearly 20% Compound Annual Growth Rate (CAGR) over the next decade, MDisrupt is positioned to cement its role as the “go to” for companies seeking top-tier healthcare expertise.

Cat Middleton, General Partner at The Venture Collective (TVC), who is joining the MDisrupt Board of Directors, shared her excitement about the investment, stating, “The future of healthcare innovation finally has the expertise infrastructure it direly needs to help the industry build, commercialize, and scale products. We believe that MDisrupt’s pioneering role in healthcare will set a new standard for innovation, and will ultimately drive better health outcomes.”

In the heart of the healthtech revolution, MDisrupt is not just a marketplace; it’s a catalyst for transformative healthcare change. With this round of funding, MDisrupt is poised to lead the charge, unlocking the doors to a healthier future for us all.

About MDISRUPT:
MDisrupt is the health technology industry’s leading health expert marketplace with over 1,500 experts from established institutions such as Blue Cross Blue Shield, CVS, Willis Towers Watson, U.S. FDA, Optum, and Cleveland Clinic. We connect healthtech and life science companies with vetted and curated health experts to help them build, commercialize and scale their health products. MDisrupt serves companies across healthtech and life science sectors including startups, scaleup and enterprise giants.
Learn more at www.mdisrupt.com

About TVC:
TVC is a transformational, early-stage venture firm backed by world class entrepreneurs and business leaders. Led by a seasoned team of venture investors, ex-founders, and investment management executives, we invest our capital, time, and network into highly defensible, fast-growing companies with the potential to solve the world’s largest problems.
Learn more at www.theventurecollective.com

Contact:
Ruby Gadelrab
[email protected]
mdisrupt.com

SOURCE MDisrupt

Netherlands-based aquaculture investment fund Aqua-Spark led the round, joined by additional investors The Kitchen Hub, Peregrine Ventures, PICO Venture Partners, MOREVC, and CPT Capital

REHOVOT, Israel , Oct. 9, 2023 — Today, FoodTech start-up Wanda Fish Technologies, Ltd., announces it has secured USD 7 million in seed funding. The round was led by Netherlands-based global aquaculture investment fund Aqua-Spark, with additional funding from returning pre-seed investors The Kitchen Hub by the Strauss Group, Peregrine Ventures, LLC, PICO Venture Partners, MOREVC, and CPT Capital, LLP. Since its inception, Wanda Fish has raised USD 10 million in funding.

Founded in 2021 by The Kitchen Hub and Daphna Heffetz, a leading figure in biotechnology-based innovation, Wanda Fish develops premium quality, cultivated fish outside of the ocean. This new injection of capital will boost Wanda Fish’s ability to accelerate the creation and increase the scale of a cultivated whole-cut filet of bluefin tuna.

These cuts replicate the texture, flavor, and nutritional value of wild-caught bluefin tuna as they comprise the fish’s muscle and fat cells and contain the same native proteins and fatty acids, including omega-3 and other essential nutrients. As a cultivated filet, Wanda Fish’s bluefin tuna has no common ocean pollutants, like mercury, and is produced under non-GMO standards.

“We are excited and feel incredibly fortunate to collaborate with Aqua-Spark in propelling our venture forward,” says Daphna Heffetz, Ph.D., co-founder and CEO of Wanda Fish. “We are on a shared mission to improve the global food value chain, creating a tasty, more sustainable future for all. This financial backing by leading global venture funds gives us significant leverage to make sustainably cultivated, cruelty-free, and ocean-friendly bluefin tuna a reality.”

Valued for its nutritional content, texture, and flavor, bluefin tuna is an expensive, sought-after species that is particularly popular with high-end sushi restaurants due to its perfect balance of fat and protein.

Further driving demand is bluefin tuna’s inaccessibility. Overfishing of bluefin tuna has pushed it to the brink of endangerment, leading governments to significantly limit fishing quotas. Meanwhile, tuna is considered unsustainable to farm due to the feed resources, pen size requirements, and difficulty of breeding in captivity. In addition, tuna is one of the oceans’ most polluted fish, often contaminated with plastic debris and extremely high levels of heavy metals such as mercury, intensifying the need for an accessible, stable supply of sustainable alternatives.

Wanda Fish has made rapid progress on key developmental breakthroughs toward achieving a whole-cut bluefin tuna prototype to provide an abundant, premium source of highly nutritious fish that will alleviate strain on the delicate ocean ecosystem. This includes forming a 3D filet structure using bluefin tuna cells, differentiated into both muscle and fat tissues. With its proprietary technique, Wanda Fish can precisely control fat levels in its end products. This enables the creation of a diverse range of filet cuts, including the highly sought-after Toro premium cut.

“In such a burgeoning and innovative sector, we are pleased to welcome Wanda Fish into our portfolio of companies based on the remarkable speed with which they’ve met significant milestones,” asserts Lissy Smit, CEO of Aqua-Spark. “We firmly believe in a future where sustainably farmed and cultivated seafood will work in concert with one another to alleviate the burden of overfishing, especially species like bluefin tuna which are deemed unsustainable to farm.”

“As the start-up’s incubator, we’ve had the privilege of witnessing the immense progress Wanda Fish has made since their inception less than two years ago,” enthuses Jonathan Berger, CEO of The Kitchen FoodTech Hub. “Wanda Fish is transforming visionary ideas into a tangible, cutting-edge product that is just steps away from reaching its prototype. This is credited to a skilled and ambitious multinational team led by Daphna Heffetz that is undoubtedly poised for a resounding success story in the thriving alternative protein space; this spells good news for an overburdened marine ecosystem.”

About Wanda Fish 

Wanda Fish is a cutting-edge company spearheading a more sustainable future for ocean seafood. Through disruptive technologies, they produce a variety of whole-cut cultivated premium fish filets outside of the ocean. The company’s first product in development is the whole-cut cultivated bluefin tuna filet composed of the fish’s muscle and fat cells. It bears the authentic texture, flavor, and nutritional richness of wild-caught fish.

The Wanda Fish team comprises a highly skilled multidisciplinary team. Daphna Heffetz, PhD, co-Founder and CEO, brings over 20 years of experience in establishing and growing biotechnology companies. Malkiel Cohen, PhD., VP of R&D at Wanda Fish, is an expert in stem cell technology and genomic engineering, and Yaron Sfadyah, LL.B & B.A., VP of Business Development at Wanda Fish, having 10+ global marketing and business development experience. Under an exclusive licensing and sponsored research agreement with Tufts University in Boston, Wanda Fish also works closely with David Kaplan, PhD, a world-leading academic authority in cellular agriculture.

For more information about Wanda Fish, please visit www.wandafish.com

About Aqua-Spark

Aqua-Spark is a global investment fund, active in 22 countries with investors across 33 countries, building a portfolio of solutions across the aquaculture value chain with the ability to transform the industry into one that is healthier, more sustainable, and more accessible. With just shy of EUR 500 million in assets under management, each investment is chosen for its potential to generate financial returns while also activating positive environmental and social outcomes.

For more information about Aqua-Spark, please visit www.aqua-spark.nl

Press Contacts:

Liat Simha | Wanda Fish: [email protected]  Tel +972-9-9742893
Oona Eager | Aqua-Spark: oona@aqua-spark.nl

Photo – https://mma.prnewswire.com/media/2241865/Wanda_Fish.jpg

SOURCE Wanda Fish Technologies

Marynenko Will Work On Various Artificial Intelligence Projects

GREENWICH, Conn., Oct. 9, 2023 — O’Shaughnessy Ventures LLC (“OSV”), an investment firm that empowers creators, has named Mykhailo Marynenko as its Engineer in Residence.

Marynenko will work on various projects involving artificial intelligence, including a new form of digital assistant that acts as a self-organizing second brain capable of learning from its user.

“I’m excited to welcome Mykhailo to OSV,” said OSV’s founder and CEO, Jim O’Shaughnessy; “the team and I were blown away by his intelligence and technical knowledge and can’t wait to see what he builds for us.”

Marynenko commented: “Joining OSV as an Engineer in Residence is an incredible opportunity to merge my passions for technology, art, and innovation. I am excited to contribute my expertise and collaborate with a diverse team to create groundbreaking solutions and experiences.”

In addition to his new role as Engineer in Residence, Marynenko was previously awarded a $100,000 O’Shaughnessy Fellowship grant, which he will continue to apply towards projects that combine technology with art and human interaction. 

About Marynenko

Marynenko is a software and hardware engineer from Ukraine.

As well as being a keen researcher of security issues, he is passionate about building modern, collaborative, performant and scalable applications.

His interest in engineering began at his father’s phone repair shop in Ukraine. His experience there led him to tinker with every technology, chipset, and circuit board he could lay his hands on. He has since applied this same mindset to complex projects, including advanced, scalable facial recognition systems, autonomous driving systems, and innovative technologies for higher education.

Currently, Marynenko is working on artificial intelligence tools, computational neuroscience research, security research, and new internet standards development.

More information about Marynenko is available via his website.

About O’Shaughnessy Ventures

OSV is a creative investment firm that empowers and inspires creators to bring their ideas to life. Founded by Jim O’Shaughnessy, a pioneer in quantitative investing, founder of O’Shaughnessy Asset Management, and author of four books on investing, OSV aims to provide financial support and to partner in growing the next life-changing creative ideas. 

OSV combines Jim’s deeply rooted interest in all things art, science, investing, and tech with his long-held desire to establish scenarios designed to help promising creators and their inspiring ideas succeed, regardless of age, location, job history, or level of education. For more information, visit https://www.osv.llc/.

Media Contact:
Ena Gong
O’Shaughnessy Ventures LLC
(917) 355-7420
366580@email4pr.com

SOURCE O’Shaughnessy Ventures LLC

Industrifonden and Navigare Ventures fund $7.3 million round

STOCKHOLM, Oct. 9, 2023 — Pixelgen Technologies^®, a leader in spatial proteomics for single cells, announced today that it has closed a Series A financing of approximately $7.3 million. The round was led by new investor Industrifonden, Sweden’s venture capital fund, and Navigare Ventures, an investor in Pixelgen’s Seed round. Proceeds from the financing will support the commercial expansion of Pixelgen’s recently launched spatial proteomics tool for analyzing cell surface proteins on single cells to transform drug discovery and basic science. 

“Pixelgen has made great progress since we emerged from stealth less than a year ago. Last month we shipped our first product to advance drug development and research in immunology, and we’ve expanded our team with top talent,” said Pixelgen CEO Simon Fredriksson, Ph.D. “As we enter this next phase of growth, we are grateful and honored to have the support and expertise of Industrifonden and Navigare Ventures and look forward to their contributions.”

In conjunction with the financing, Industrifonden Senior Investment Director Patrik Sobocki, Ph.D., will join Pixelgen’s board of directors. Sobocki brings decades of experience in healthcare, technology, and entrepreneurship to the board, in addition to his background in international research and development and commercial leadership roles in global pharmaceutical companies.

“We are extremely excited to back Pixelgen. Its team of strong serial entrepreneurs with unicorn outcomes and a unique technology foundation combining advanced molecular research and computational innovation fit perfectly with Industrifonden’s deep tech investment strategy and expertise in computational biology. We are honored to support Simon and his team to become a category leader within spatial proteomics in the coming decade,” said Sobocki. 

“With category-defining technology and applications in rapidly expanding markets, Pixelgen is well positioned for growth,” added Navigare Ventures Investment Manager Alex Basu, Ph.D., a Pixelgen board member. “We look forward to continuing to support Pixelgen as it expands and builds its portfolio of products for drug research and development.”

About Pixelgen Technologies

Pixelgen Technologies AB was founded in 2020 by a team of passionate, experienced innovators and entrepreneurs with a vision to bring a new spatial understanding to biology by mapping cell surface proteins and their spatial inter-relationships. The company has developed Molecular Pixelation, a DNA-based visualization technology for analyzing cell surface proteins, to gain novel insights into cellular activity that will advance better medicines and diagnostics. Pixelgen is headquartered in Stockholm, Sweden.

Contacts

Corporate:
Annika Branting
[email protected] 
+46 762-69 68 46

Media:
Susan Thomas
[email protected]
+1 (619) 540-9195

SOURCE Pixelgen Technologies